Galleri is coming to you!

Galleri is a proactive blood test that can be done annually, screening for many aggressive cancers before symptoms appear.1,2,3 

Attend an onsite event

Book an appointment for the onsite blood draw event and complete your Galleri health questionnaire.
 

June 3rd: 12pm - 6pm 

Hebron Plant 

2700 Earhart Ct, Hebron, KY 41048

 

June 25th: 11am - 2pm 

Salem Plant 

9 Northwestern Dr, Salem, NH 03079

Visit a local lab

Request the test through this website. If approved, the kit will be mailed to you, and you can schedule an appointment with a blood draw technician at home or a local lab.

Request Galleri

Galleri is available by prescription only. By requesting the test and completing the health questionnaire, you're requesting a prescription from an independent telemedicine provider.

The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. Galleri does not diagnose cancer, diagnostic workup required to confirm cancer. The Galleri test identifies DNA in the bloodstream shed by cancer cells and does not predict future genetic risk for cancer. Galleri should be used in addition to healthcare provider recommended screening tests.

Introducing Galleri multi-cancer early detection test

Galleri is a proactive blood test that can be done annually, screening for many aggressive cancers before symptoms appear.1,2,3

Request Galleri

Galleri is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cindy testimonial preview

Patient Story: Roger, Cancer Signal Detected with the Galleri test

Patient Story: Roger, Cancer Signal Detected with the Galleri test

Galleri is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Galleri Brochure en Espanol: 
    US Galleri ES Flyer

Who is eligible?

The Galleri test is available at no cost to eligible Gates employees and their dependents aged 40-49 with risk factors and 50 years old or older.

Employees4

  • 50 years and older
  • Ages 40 to 49 with additional risk factors
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 5 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

* excludes basal or squamous cell carcinoma of the skin

** excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

Please note that the Galleri test is not available for people who are currently pregnant.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Dependents / spouses4

  • 50 years and older
  • Ages 40 to 49 with additional risk factors
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 5 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

* excludes basal or squamous cell carcinoma of the skin

** excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

Please note that the Galleri test is not available for people who are currently pregnant.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Note to dependents: Use the employee’s Access ID when requesting the test. Use your personal information to request the test.

While individuals ages 40-49 with certain risk factors may be at an elevated risk for cancer, Galleri was only studied in a population age 50 and older.5

Our testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes. Use your employer Access ID to start an online health questionnaire about your medical history. Galleri is available by prescription only. By requesting the test and completing the questionnaire, you're requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes Galleri, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your results are ready - about 2 weeks after your blood is received at the GRAIL laboratory.

What is Galleri?

Supported by robust clinical data, Galleri sets the standard for multi-cancer early detection — 20,000+ individuals participated in large clinical studies.
  • What is Galleri poster 2

    Que es Galleri en Español

  • illustrated graphic video explaining how the Galleri test works

    How does the Galleri Test work? en Español

  • Understanding cancer signal detected

    Galleri: Understanding a Cancer Signal Detected result - En Español

  • Understanding no cancer signal detected

    Galleri: Understanding a No Cancer Signal Detected result - en Español

1 / 4

Frequently Asked Questions for Gates

Additional Frequently Asked Questions about the Galleri test

The Galleri test is available at no cost to eligible Gates employees and their dependents aged 40-49 with risk factors and 50 years old and older.

To access the Galleri test as a covered benefit, you must request the test through this webpage. 

When requesting through this website, an independent telemedicine healthcare provider will review your request and order the test if appropriate. The test is available by prescription only.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit for eligible Gates employees and dependents.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule.

To request the test you will need an Access ID.

Your Access ID is your Employee ID. If you have any issues finding your Employee ID please contact GRAIL Customer Service at (833) 694‑2553. If you are a dependent leveraging the Galleri benefit, please use the Employee's Employee ID as your Access ID.

If you are not eligible for the benefit under Gates program, you may be able to use pre-tax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test on galleri.com. Check with your FSA or HSA administrator or insurance provider to determine eligibility.

Under the Gates benefit program employees and eligible dependents for the Galleri test will be able to complete the Galleri test 12 months from the last date of service.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent telemedicine provider will review your request and order the test, if appropriate.

The Galleri test is provided at no cost to eligible employees and dependents only when obtained through this authorized site https://www.Galleri.com/Gates.

The blood draw associated with Galleri must occur on a date you are covered under this employee benefit.

Employees are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after Gates benefit coverage has ended.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. American Cancer Society Cancer Facts and Figures 2023. Available at: https://www.cancer.org/content/... GRAIL, Inc. Data on file GA-2021-0065
  3. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  4. Christine Clark Dur, Margaret McCusker. Evaluation of factors associated with elevated cancer risk among persons under age 50. GRAIL, LLC. Data on File GR-2023-0098
  5. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi:10.1016/S0140-6736(23)01700-2